Azasan Articles
SONIC trial data "could challenge treatment protocol" for CD
13 October 2008
US FDA calls for tougher warnings on TNF-alpha drugs on 240 cases of histoplasmosis
15 September 2008
EU approves Remicade label update for CD
16 October 2006
CMHP issues positive opinion to S-P/Centocor's Remicade edging; closer to approval in the EU
6 February 2006
Positive data for CellCept in children
18 April 2005
UK govt's $7.3M for pharmacogenetics
28 June 2004
Tokyo pharma stocks - week to April 5
12 April 2004
Positive new data for Roche's CellCept
22 March 2004
Second FDA drug imports "blitz" finds 80% come from Canada
9 February 2004
Novartis' Certican tops azathioprine
21 April 2003
CellCept switch boosts renal function
6 May 2002
Rapamune transplant drug approved in Canada
6 June 2001
Santarus completes $33.2 mill placement
9 March 2001
Overseas sales boost Orion Pharma
10 November 2000
Roche's CellCept gets expanded label in USA
10 August 2000
AHP weathers the storm with first Rapamune approval
17 September 1999
Counsel Corp to float Faro
16 June 1999
Faro Acquires GW Products For $105 Mill
16 December 1998
AHP's Rapamune Improves 6-Month Graft Survival
16 July 1998
CellCept Use Should Be Broadened, Says Panel
20 January 1998
Roche's Zenapax Gets First Approval For Transplants
17 December 1997
Roche's Zenapax Gets Backing Of FDA Panel
23 October 1997
Phase III Results With IMTIX' Antirejection Antibody
23 October 1997
Six-Month Zenapax Data; Global Filing Set For 1H97
24 February 1997
Zenapax Results Boost PDL And Roche
7 October 1996
SangStat Transplant Drug Shows Promise In Phase II
26 February 1996
EMEA Approves Roche's CellCept
26 February 1996
Mycophenolate Approval in Europe Imminent, Says Roche
19 February 1996
CellCept Launched In 1st Market
3 July 1995
First Approval For Roche's Mycophenolate Mofetil
15 May 1995
FDA Panel Backs Cellcept For Acute Rejection
10 April 1995
World Immunology, Rheumatology Markets
28 November 1994
Fujisawa Launches Prograf In The UK
31 October 1994
CICLOSPORIN'S ROLE IN BOWEL INFLAMMATION
4 July 1994
NEW THERAPIES FOR MULTIPLE SCLEROSIS
4 April 1994
IMPACT OF SWEDISH REFERENCE PRICING
10 January 1994
PROGRAF TRIALS BEGIN IN UK
29 November 1993
FDA PANEL ENDORSES BERLEX' BETASERON
29 March 1993
ABBREVIATED DRUG NAMES WARNING
7 December 1992
Showing 1-47 of 47 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
